Syndax Pharmaceuticals

SNDX · NASDAQ

$13.25+$0.16 (+1.22%)TodayMarket closed · Oct 20, 7:33 PM ET

Prev close $13.09

SNDX analyst rating

BuyConsensus of 10 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy10
Hold0
Underperform0
Sell0

12-month price target · 14 analysts

Average $39.78 (+200.2% upside)

Low: $26.26
Now: $13.25
High: $59.85

Upgrades and downgrades

The latest rating actions, newest first

SNDX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 13, 2026	Maintains	Buy	$38.00	41%
UBS	Aug 21, 2026	Maintains	Buy	$37.00 → $33.00	45%
JP Morgan	Aug 11, 2026	Maintains	Overweight	$44.00 → $40.00	48%
HC Wainwright & Co.	Aug 5, 2026	Maintains	Buy	$40.00 → $38.00	41%
HC Wainwright & Co.	Jul 15, 2026	Maintains	Buy	$40.00	41%
HC Wainwright & Co.	Jun 12, 2026	Maintains	Buy	$40.00	41%
HC Wainwright & Co.	May 22, 2026	Maintains	Buy	$40.00	41%
UBS	May 13, 2026	Maintains	Buy	$38.00 → $37.00	45%
Barclays	May 1, 2026	Maintains	Overweight	$35.00 → $37.00	46%
Goldman Sachs	Apr 1, 2026	Maintains	Buy	$28.00 → $34.00	53%

The case for and against

Updated Oct 18, 2026

Bull case

Syndax Pharmaceuticals is attractive because its core Revuforj franchise is showing expanding clinical and commercial traction across genetically defined AML, including a 97% CRc in frontline combination data, 86% ORR in real-world monotherapy, and durable post-HSCT outcomes with estimated 12-month OS of 95% and RFS of 79%. Even after the Phase 2 MAXPIRe miss in IPF, the broader thesis remains intact because axatilimab’s cGVHD opportunity and royalty stream were never tied to IPF, while the program continues to advance in newly diagnosed cGVHD and could still support a meaningful anti-CSF-1R franchise. Beyond near-term catalysts in 4Q26, the company adds capital-efficient optionality through SNDX-62122 in MF and SNDX-4321 in EGFR-mutated NSCLC, widening the growth runway without materially disrupting its path toward profitability.

Bear case

Syndax Pharmaceuticals is a high-risk, clinical-stage biopharmaceutical company whose valuation depends heavily on future success that is still unproven, including meaningful efficacy and eventual regulatory approval for revumenib, axatilimab, and other candidates. Its pipeline is exposed to substantial clinical, competitive, and commercial uncertainty, while the need for additional equity financing raises dilution risk and underscores the lack of near-term self-funding capacity. Even the bullish framework in the excerpts relies on discounted FY32 earnings of $4.31 to $5.61, which highlights that any setback in trials, approval timelines, or market adoption could materially pressure the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.